Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

754 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Survival Outcomes Associated With Radiological Progressive Disease Subtypes in Patients With Atezolizumab and Bevacizumab-Treated HCC.
Matono T, Tada T, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Nishikawa H, Tanaka K, Tsuji K, Ishikawa T, Tajiri K, Koshiyama Y, Toyoda H, Ogawa C, Hatanaka T, Kakizaki S, Kawata K, Ohama H, Tada F, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Nishimura T, Imai M, Kosaka H, Naganuma A, Aoki T, Kuroda H, Yata Y, Nakamura Y, Yoshida O, Nakamura S, Enomoto H, Kaibori M, Hiasa Y, Kudo M; Real‐life Practice Experts for HCC (RELPEC) Study Group; Hepatocellular Carcinoma Experts from 48 clinics in Japan (HCC 48) Group. Matono T, et al. Among authors: enomoto h. J Gastroenterol Hepatol. 2025 Jan 22. doi: 10.1111/jgh.16884. Online ahead of print. J Gastroenterol Hepatol. 2025. PMID: 39844393
Evaluation of Treatment Outcomes Using dNLR and GNRI in Combination Therapy With Atezolizumab and Bevacizumab for Hepatocellular Carcinoma.
Naganuma A, Kakizaki S, Hiraoka A, Tada T, Hatanaka T, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Toyoda H, Ogawa C, Nishikawa H, Nishimura T, Kawata K, Kosaka H, Hirooka M, Yata Y, Ohama H, Kuroda H, Matono T, Aoki T, Kanayama Y, Tanaka K, Tada F, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Nakamura S, Enomoto H, Kaibori M, Hiasa Y, Kudo M, Kumada T. Naganuma A, et al. Among authors: enomoto h. Cancer Med. 2025 Jan;14(2):e70618. doi: 10.1002/cam4.70618. Cancer Med. 2025. PMID: 39840727 Free article.
Feasibility and Safety of Double-Wire Technique for Microcatheter Navigation Beyond Tortuous Internal Carotid Siphon: A Propensity Score-Matched Study.
Fuga M, Ishibashi T, Kan I, Hataoka S, Kato N, Nagayama G, Sano T, Enomoto H, Shirokane K, Teshigawara A, Murayama Y. Fuga M, et al. Among authors: enomoto h. World Neurosurg. 2025 Jan 10;194:123592. doi: 10.1016/j.wneu.2024.123592. Online ahead of print. World Neurosurg. 2025. PMID: 39725289 Free article.
Efficacy of durvalumab plus tremelimumab treatment for unresectable hepatocellular carcinoma in immunotherapy era clinical practice.
Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ohama H, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Kawata K, Naganuma A, Kosaka H, Matono T, Kuroda H, Yata Y, Nishikawa H, Imai M, Aoki T, Ochi H, Tada F, Nakamura S, Nakamura Y, Nouso K, Morishita A, Itokawa N, Okubo T, Arai T, Tsutsui A, Nagano T, Tanaka K, Tanaka H, Koshiyama Y, Kanayama Y, Noritake H, Enomoto H, Kaibori M, Hiasa Y, Kudo M, Kumada T; RELPEC Group and HCC 48 Group. Hiraoka A, et al. Among authors: enomoto h. Hepatol Res. 2024 Nov 11. doi: 10.1111/hepr.14136. Online ahead of print. Hepatol Res. 2024. PMID: 39526824
Prognostic impact of age on outcomes of hepatic decompensation in patients with compensated cirrhosis (CHESS2102): an international, multicenter cohort study.
Liu S, Li J, Wong Y, Yim HJ, Hirooka M, Enomoto H, Xie Q, Dai E, Hanafy AS, Cao Z, Zhao L, Teh KB, Kim TH, Jung YK, Koizumi Y, Hiasa Y, Nishimura T, Iijima H, Tian Q, Guo X, Jia Y, Sun J, Liu C, Qi X. Liu S, et al. Among authors: enomoto h. MedComm (2020). 2024 Nov 3;5(11):e781. doi: 10.1002/mco2.781. eCollection 2024 Nov. MedComm (2020). 2024. PMID: 39492833 Free PMC article.
Clinical validation of the suppressive impact of letrozole on liver fibrosis in patients with breast cancer undergoing continuous letrozole administration: A retrospective study.
Ohkawa K, Nakabori T, Mukai K, Kozumi K, Urabe M, Kai Y, Takada R, Ikezawa K, Yamaguchi Y, Nagao T, Enomoto H, Tachiki H, Higuchi A, Watanabe N, Nakayama T. Ohkawa K, et al. Among authors: enomoto h. PLoS One. 2024 Oct 24;19(10):e0311930. doi: 10.1371/journal.pone.0311930. eCollection 2024. PLoS One. 2024. PMID: 39446769 Free PMC article.
Feasibility of Double-Deployment Small-Diameter Covered Metallic Stent for Malignant Distal Biliary Obstruction (with Video).
Nakano R, Shiomi H, Okamoto M, Kawase Y, Yoshihara K, Yoshioka R, Kawata S, Yuri Y, Takashima T, Aizawa N, Ikeda N, Nishimura T, Fukunishi S, Enomoto H. Nakano R, et al. Among authors: enomoto h. Diagnostics (Basel). 2024 Oct 7;14(19):2233. doi: 10.3390/diagnostics14192233. Diagnostics (Basel). 2024. PMID: 39410637 Free PMC article.
754 results